ALB and lung adenocarcinoma: According to the NCCN guidelines (version 5.2023) [17], pemetrexed-based immunotherapy is usually used as the preferred treatment in lung adenocarcinoma, but paclitaxel-based therapies such as carboplatin + albumin-bound paclitaxel + atezolizumab and carboplatin + paclitaxel + bevacizumab + atezolizumab are also recommended in the “other recommended” category.